Login to Your Account

Other News To Note

Thursday, October 11, 2012
• Autism Therapeutics LLC, of New York, had a Type C Guidance Meeting with the FDA regarding Phase III development of Zydis ODT Fluoxetine for autism.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription